Fractyl Health (GUTS)
Develops clinical-stage therapies for obesity and type 2 diabetes through the gut and pancreas.
Fractyl Health, Inc. (GUTS) Discusses Commercialization Strategy for Investigational Post-GLP-1 Procedural Therapy Transcript
Fractyl Health, Inc. (GUTS) Discusses Commercialization Strategy for Investigational Post-GLP-1 Procedural Therapy Transcript
Fractyl Health Eyes Q4 Revita Data, Launches Rejuva Gene Therapy Trial
Fractyl Health NASDAQ: GUTS is advancing two one-time treatment approaches intended to provide durable benefits for obesity, type 2 diabetes and related metabolic diseases, Chief Executive Officer Harith Rajagopalan said during a Canaccord discussion.
Fractyl Health, Inc. (GUTS) Q2 2026 Earnings Call Transcript
Fractyl Health, Inc. (GUTS) Q2 2026 Earnings Call Transcript
Fractyl Health Q2 Earnings Call Highlights
Fractyl Health NASDAQ: GUTS said its Revita endoscopic procedure showed durable weight-maintenance results one year after patients discontinued GLP-1 therapy, while the company reaffirmed plans to report pivotal trial data in early fourth-quarter 2026 and pursue a potential FDA De Novo submission later in the year.
Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026
BURLINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will report financial results for the second quarter 2026 and provide business updates on Monday, August 10, 2026, at 4:30 p.m. ET.
Fractyl Health to Participate in Upcoming Investor Events
BURLINGTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of the Company, will be participating in the following upcoming investor conferences:
Fractyl Health Stock Up on Encouraging One-Year Revita Study Results
GUTS' shares surge after Revita patients retain up to 84% of GLP-1-induced weight loss in a year, compared with 46% for sham patients.
Fractyl Health, Inc. (GUTS) Discusses 1-Year REMAIN-1 Data Demonstrating Durable Weight Maintenance After GLP-1 Discontinuation Transcript
Fractyl Health, Inc. (GUTS) Discusses 1-Year REMAIN-1 Data Demonstrating Durable Weight Maintenance After GLP-1 Discontinuation Transcript
Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy
BURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced the appointment of Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy.
Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates
Next anticipated Revita ® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 Early Q4 2026 timing for topline 6-month randomized data from the REMAIN-1 Pivotal Cohort and late Q4 2026 timing for potential FDA De Novo marketing application submission in post-GLP-1 weight maintenance reaffirmed Clinical Trial Application authorization of RJVA-001 first-in-human study in the Netherlands for T2D; first-in-human dosing anticipated in second half of 2026 reiterated Cash runway guidance into early 2027, beyond anticipated Pivotal data readout reiterated Conference call today at 4:30 p.m. ET BURLINGTON, Mass.
Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes
Authorization advances Fractyl Health to a dual clinical-stage company, with Revita ® in pivotal development for post-GLP-1 weight maintenance and Rejuva ® entering first-in-human studies for type 2 diabetes
Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference
BURLINGTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will report financial results for the first quarter 2026 and provide business updates on Tuesday, May 12, 2026, at 4:30 p.m.
Fractyl Health, Inc. (NASDAQ:GUTS) Receives $5.40 Average Price Target from Analysts
Shares of Fractyl Health, Inc. (NASDAQ: GUTS - Get Free Report) have earned an average rating of "Hold" from the five brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company.
Fractyl Health Q4 Earnings Call Highlights
Fractyl Health (NASDAQ: GUTS) used its fourth-quarter and full-year 2025 results call to sharpen its investment narrative around Revita, its endoscopic procedure aimed at helping patients maintain weight loss after stopping GLP-1 drugs. Management said recent analyses of clinical data have clarified which patients benefit most and how procedural "dose" appears to drive outcomes, while also
Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript
Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript
Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026
BURLINGTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes, today announced that it will report financial results for the fourth quarter and full year 2025 and provide business updates on Tuesday, March 24, 2026, at 4:30 p.m.
Fractyl Health, Inc. (GUTS) Moves to Buy: Rationale Behind the Upgrade
Fractyl Health, Inc. (GUTS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Fractyl Health, Inc. (GUTS) Loses 77.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Fractyl Health, Inc. (GUTS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Short Interest in Fractyl Health, Inc. (NASDAQ:GUTS) Increases By 22.6%
Fractyl Health, Inc. (NASDAQ: GUTS - Get Free Report) was the recipient of a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 14,901,084 shares, a growth of 22.6% from the January 15th total of 12,151,106 shares. Approximately 14.7% of the company's stock are short sold.